Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion reports 43 per cent rise in half-year revenue

Actelion reports 43 per cent rise in half-year revenue

19th July 2007

Actelion has announced its financial results for the first half of 2007, with the company generating total net revenues of CHF 626.4 million (255.4 million pounds), a rise of 43 per cent on the same period last year.

The firm reported a net loss of CHF 53 million for the first half of the fiscal year, a drop from a net loss of CHF 105 million recorded for the first half of 2006.

Following the publication of these results, the company has increased its guidance for the full financial year, forecasting net revenues of between CHF 1.275 billion and CHF 1.315 billion – up from CHF 1.2 billion to CHF 1.245 billion, with a corresponding rise in predicted cash EBIT.

Jean-Paul Clozel, chief executive officer of Actelion, said: “In the first six months of 2007, Actelion has again demonstrated that it is indeed a biotech innovation leader.

“We have expanded our base for future accelerated growth, with multiple Phase III programmes either enrolling or about to enroll and other earlier-stage clinical programs advancing well.”

He added that the firm’s products have been well integrated into the pharmaceutical market, with their position to be strengthened through the inclusion of new clinical data sets into their product labelling.

Furthermore, the company has forecast continued product revenue growth in the future, which will facilitate ongoing investment into its research and development pipeline.

After the publication of its first-quarter results earlier this year, Actelion announced that it is fully prepared for a strategy of long-term growth.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.